Back to Newsroom

Arrowhead Pharmaceuticals to Present Data on ARC-AAT at The Liver Meeting(R)

PASADENA, Calif.–(BUSINESS WIRE)– Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will make two presentations on ARC-AAT, the company’s investigational medicine for the treatment of liver disease associated with alpha-1 antitrypsin deficiency (AATD), at The Liver Meeting® 2016, the Annual Meeting of the American Association for the Study of Liver Disease (AASLD) being held on November 11-15, 2016, in Boston.

Click here to read the full release